nodes	percent_of_prediction	percent_of_DWPC	metapath
Lamivudine—ABCC3—Cisplatin—bone cancer	0.0859	0.117	CbGbCtD
Lamivudine—ABCC1—Epirubicin—bone cancer	0.0665	0.0907	CbGbCtD
Lamivudine—ABCC3—Doxorubicin—bone cancer	0.0576	0.0785	CbGbCtD
Lamivudine—ABCC3—Methotrexate—bone cancer	0.0558	0.0761	CbGbCtD
Lamivudine—SLC22A2—Cisplatin—bone cancer	0.0478	0.0652	CbGbCtD
Lamivudine—ABCC2—Carboplatin—bone cancer	0.0457	0.0623	CbGbCtD
Lamivudine—ABCC4—Methotrexate—bone cancer	0.0426	0.0581	CbGbCtD
Lamivudine—ABCG2—Carboplatin—bone cancer	0.0413	0.0563	CbGbCtD
Lamivudine—ABCC2—Cisplatin—bone cancer	0.0391	0.0532	CbGbCtD
Lamivudine—ABCC1—Doxorubicin—bone cancer	0.0354	0.0482	CbGbCtD
Lamivudine—ABCG2—Cisplatin—bone cancer	0.0353	0.0481	CbGbCtD
Lamivudine—ABCC1—Methotrexate—bone cancer	0.0343	0.0467	CbGbCtD
Lamivudine—ABCC2—Doxorubicin—bone cancer	0.0262	0.0357	CbGbCtD
Lamivudine—ABCC2—Methotrexate—bone cancer	0.0254	0.0346	CbGbCtD
Lamivudine—ABCG2—Doxorubicin—bone cancer	0.0237	0.0323	CbGbCtD
Lamivudine—ABCG2—Methotrexate—bone cancer	0.0229	0.0312	CbGbCtD
Lamivudine—SLC22A6—Methotrexate—bone cancer	0.0186	0.0253	CbGbCtD
Lamivudine—ABCB1—Cisplatin—bone cancer	0.0127	0.0174	CbGbCtD
Lamivudine—ABCB1—Doxorubicin—bone cancer	0.00853	0.0116	CbGbCtD
Lamivudine—ABCB1—Methotrexate—bone cancer	0.00826	0.0113	CbGbCtD
Lamivudine—DCK—Doxorubicin—Epirubicin—bone cancer	0.0013	0.519	CbGdCrCtD
Lamivudine—DCK—Epirubicin—Doxorubicin—bone cancer	0.00121	0.481	CbGdCrCtD
Lamivudine—ABCC1—Sphingosine 1-phosphate (S1P) pathway—GNA11—bone cancer	0.000784	0.00519	CbGpPWpGaD
Lamivudine—ABCC3—Fluoropyrimidine Activity—DHFR—bone cancer	0.000745	0.00493	CbGpPWpGaD
Lamivudine—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000731	0.00484	CbGpPWpGaD
Lamivudine—NME1—Posttranslational regulation of adherens junction stability and dissassembly—MET—bone cancer	0.000729	0.00483	CbGpPWpGaD
Lamivudine—ABCC4—Ectoderm Differentiation—BCOR—bone cancer	0.000724	0.0048	CbGpPWpGaD
Lamivudine—ABCC4—Fluoropyrimidine Activity—DHFR—bone cancer	0.000701	0.00464	CbGpPWpGaD
Lamivudine—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000685	0.00454	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000684	0.00453	CbGpPWpGaD
Lamivudine—ABCC3—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000647	0.00429	CbGpPWpGaD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—CDK4—bone cancer	0.000645	0.00427	CbGpPWpGaD
Lamivudine—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000617	0.00408	CbGpPWpGaD
Lamivudine—PGK1—Carbohydrate metabolism—ENO2—bone cancer	0.000602	0.00399	CbGpPWpGaD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.000591	0.00391	CbGpPWpGaD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000565	0.00374	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000552	0.00366	CbGpPWpGaD
Lamivudine—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	0.000514	0.0034	CbGpPWpGaD
Lamivudine—ABCC2—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000513	0.0034	CbGpPWpGaD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—CDK4—bone cancer	0.000489	0.00324	CbGpPWpGaD
Lamivudine—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000489	0.00324	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—NDUFA12—bone cancer	0.000483	0.0032	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—NDUFA12—bone cancer	0.000483	0.0032	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—NDUFA12—bone cancer	0.000483	0.0032	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00047	0.00311	CbGpPWpGaD
Lamivudine—Zalcitabine—CYP3A4—bone cancer	0.000463	0.598	CrCbGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000428	0.00283	CbGpPWpGaD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—MMP9—bone cancer	0.000405	0.00268	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—NT5C3A—bone cancer	0.0004	0.00265	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—NT5C3A—bone cancer	0.0004	0.00265	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—NT5C3A—bone cancer	0.0004	0.00265	CbGpPWpGaD
Lamivudine—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.0004	0.00265	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—NDUFA12—bone cancer	0.000394	0.00261	CbGpPWpGaD
Lamivudine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000393	0.00261	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000389	0.00258	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000384	0.00254	CbGpPWpGaD
Lamivudine—NME1—Posttranslational regulation of adherens junction stability and dissassembly—EGFR—bone cancer	0.000369	0.00244	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—NDUFA12—bone cancer	0.000366	0.00242	CbGpPWpGaD
Lamivudine—ABCC4—Platelet degranulation—SPARC—bone cancer	0.000353	0.00233	CbGpPWpGaD
Lamivudine—ABCC1—S1P1 pathway—PTGS2—bone cancer	0.000341	0.00226	CbGpPWpGaD
Lamivudine—ABCC4—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000336	0.00222	CbGpPWpGaD
Lamivudine—NME2—Metabolism—NDUFA12—bone cancer	0.000335	0.00222	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—NT5C3A—bone cancer	0.000326	0.00216	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000325	0.00216	CbGpPWpGaD
Lamivudine—Cytarabine—CYP3A4—bone cancer	0.000311	0.402	CrCbGaD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000311	0.00206	CbGpPWpGaD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—MMP9—bone cancer	0.000307	0.00203	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—NT5C3A—bone cancer	0.000303	0.00201	CbGpPWpGaD
Lamivudine—NME2—Metabolism—NT5C3A—bone cancer	0.000277	0.00184	CbGpPWpGaD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—TP53—bone cancer	0.000275	0.00182	CbGpPWpGaD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.00027	0.00179	CbGpPWpGaD
Lamivudine—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000269	0.00178	CbGpPWpGaD
Lamivudine—NME1—Metabolism—NDUFA12—bone cancer	0.000254	0.00168	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000241	0.0016	CbGpPWpGaD
Lamivudine—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000241	0.0016	CbGpPWpGaD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.00023	0.00152	CbGpPWpGaD
Lamivudine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00023	0.00152	CbGpPWpGaD
Lamivudine—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000217	0.00193	CcSEcCtD
Lamivudine—Muscular weakness—Doxorubicin—bone cancer	0.000217	0.00193	CcSEcCtD
Lamivudine—Renal failure—Methotrexate—bone cancer	0.000215	0.00192	CcSEcCtD
Lamivudine—Neutropenia—Epirubicin—bone cancer	0.000215	0.00191	CcSEcCtD
Lamivudine—Dysuria—Epirubicin—bone cancer	0.000215	0.00191	CcSEcCtD
Lamivudine—Abdominal distension—Doxorubicin—bone cancer	0.000214	0.00191	CcSEcCtD
Lamivudine—Stomatitis—Methotrexate—bone cancer	0.000213	0.0019	CcSEcCtD
Lamivudine—Influenza—Doxorubicin—bone cancer	0.000213	0.00189	CcSEcCtD
Lamivudine—Dysphagia—Doxorubicin—bone cancer	0.000213	0.00189	CcSEcCtD
Lamivudine—Pollakiuria—Epirubicin—bone cancer	0.000212	0.00189	CcSEcCtD
Lamivudine—NME1—Metabolism—NT5C3A—bone cancer	0.00021	0.00139	CbGpPWpGaD
Lamivudine—Sweating—Methotrexate—bone cancer	0.00021	0.00187	CcSEcCtD
Lamivudine—Feeling abnormal—Cisplatin—bone cancer	0.00021	0.00187	CcSEcCtD
Lamivudine—Pancreatitis—Doxorubicin—bone cancer	0.000208	0.00186	CcSEcCtD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—TP53—bone cancer	0.000208	0.00138	CbGpPWpGaD
Lamivudine—Hyperglycaemia—Epirubicin—bone cancer	0.000207	0.00185	CcSEcCtD
Lamivudine—Hepatobiliary disease—Methotrexate—bone cancer	0.000207	0.00185	CcSEcCtD
Lamivudine—Epistaxis—Methotrexate—bone cancer	0.000206	0.00184	CcSEcCtD
Lamivudine—Bronchitis—Doxorubicin—bone cancer	0.000204	0.00182	CcSEcCtD
Lamivudine—Agranulocytosis—Methotrexate—bone cancer	0.000204	0.00182	CcSEcCtD
Lamivudine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000203	0.00181	CcSEcCtD
Lamivudine—Pancytopenia—Doxorubicin—bone cancer	0.000202	0.0018	CcSEcCtD
Lamivudine—Renal failure—Epirubicin—bone cancer	0.000201	0.00179	CcSEcCtD
Lamivudine—Body temperature increased—Cisplatin—bone cancer	0.000201	0.00179	CcSEcCtD
Lamivudine—Neuropathy peripheral—Epirubicin—bone cancer	0.000201	0.00179	CcSEcCtD
Lamivudine—Jaundice—Epirubicin—bone cancer	0.0002	0.00178	CcSEcCtD
Lamivudine—Stomatitis—Epirubicin—bone cancer	0.0002	0.00178	CcSEcCtD
Lamivudine—Dysuria—Doxorubicin—bone cancer	0.000199	0.00177	CcSEcCtD
Lamivudine—Neutropenia—Doxorubicin—bone cancer	0.000199	0.00177	CcSEcCtD
Lamivudine—Hepatitis—Methotrexate—bone cancer	0.000196	0.00175	CcSEcCtD
Lamivudine—Sweating—Epirubicin—bone cancer	0.000196	0.00175	CcSEcCtD
Lamivudine—Pollakiuria—Doxorubicin—bone cancer	0.000196	0.00175	CcSEcCtD
Lamivudine—Pharyngitis—Methotrexate—bone cancer	0.000195	0.00174	CcSEcCtD
Lamivudine—Hepatobiliary disease—Epirubicin—bone cancer	0.000194	0.00173	CcSEcCtD
Lamivudine—Epistaxis—Epirubicin—bone cancer	0.000193	0.00172	CcSEcCtD
Lamivudine—Sinusitis—Epirubicin—bone cancer	0.000192	0.00171	CcSEcCtD
Lamivudine—Hyperglycaemia—Doxorubicin—bone cancer	0.000192	0.00171	CcSEcCtD
Lamivudine—Agranulocytosis—Epirubicin—bone cancer	0.000191	0.0017	CcSEcCtD
Lamivudine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000188	0.00167	CcSEcCtD
Lamivudine—Hypersensitivity—Cisplatin—bone cancer	0.000187	0.00167	CcSEcCtD
Lamivudine—Renal failure—Doxorubicin—bone cancer	0.000186	0.00166	CcSEcCtD
Lamivudine—Erythema multiforme—Methotrexate—bone cancer	0.000186	0.00166	CcSEcCtD
Lamivudine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000186	0.00166	CcSEcCtD
Lamivudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000185	0.00123	CbGpPWpGaD
Lamivudine—Stomatitis—Doxorubicin—bone cancer	0.000185	0.00165	CcSEcCtD
Lamivudine—Jaundice—Doxorubicin—bone cancer	0.000185	0.00165	CcSEcCtD
Lamivudine—Rhinitis—Epirubicin—bone cancer	0.000184	0.00164	CcSEcCtD
Lamivudine—Hepatitis—Epirubicin—bone cancer	0.000184	0.00164	CcSEcCtD
Lamivudine—Hypoaesthesia—Epirubicin—bone cancer	0.000183	0.00163	CcSEcCtD
Lamivudine—Asthenia—Cisplatin—bone cancer	0.000182	0.00163	CcSEcCtD
Lamivudine—Pharyngitis—Epirubicin—bone cancer	0.000182	0.00163	CcSEcCtD
Lamivudine—Sweating—Doxorubicin—bone cancer	0.000182	0.00162	CcSEcCtD
Lamivudine—Connective tissue disorder—Epirubicin—bone cancer	0.000181	0.00161	CcSEcCtD
Lamivudine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000179	0.0016	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000179	0.00118	CbGpPWpGaD
Lamivudine—Epistaxis—Doxorubicin—bone cancer	0.000179	0.00159	CcSEcCtD
Lamivudine—Sinusitis—Doxorubicin—bone cancer	0.000178	0.00158	CcSEcCtD
Lamivudine—Immune system disorder—Methotrexate—bone cancer	0.000177	0.00158	CcSEcCtD
Lamivudine—Mediastinal disorder—Methotrexate—bone cancer	0.000177	0.00158	CcSEcCtD
Lamivudine—Agranulocytosis—Doxorubicin—bone cancer	0.000177	0.00158	CcSEcCtD
Lamivudine—Chills—Methotrexate—bone cancer	0.000176	0.00157	CcSEcCtD
Lamivudine—NT5C—Metabolism—ENO2—bone cancer	0.000175	0.00116	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—ENO2—bone cancer	0.000175	0.00116	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—ENO2—bone cancer	0.000175	0.00116	CbGpPWpGaD
Lamivudine—DCK—Metabolism—NDUFA12—bone cancer	0.000174	0.00115	CbGpPWpGaD
Lamivudine—Diarrhoea—Cisplatin—bone cancer	0.000174	0.00155	CcSEcCtD
Lamivudine—Erythema multiforme—Epirubicin—bone cancer	0.000174	0.00155	CcSEcCtD
Lamivudine—Alopecia—Methotrexate—bone cancer	0.000174	0.00155	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000173	0.00114	CbGpPWpGaD
Lamivudine—Erythema—Methotrexate—bone cancer	0.000171	0.00152	CcSEcCtD
Lamivudine—Malnutrition—Methotrexate—bone cancer	0.000171	0.00152	CcSEcCtD
Lamivudine—PGK1—Disease—ENO2—bone cancer	0.000171	0.00113	CbGpPWpGaD
Lamivudine—Rhinitis—Doxorubicin—bone cancer	0.000171	0.00152	CcSEcCtD
Lamivudine—Hepatitis—Doxorubicin—bone cancer	0.00017	0.00152	CcSEcCtD
Lamivudine—Hypoaesthesia—Doxorubicin—bone cancer	0.000169	0.00151	CcSEcCtD
Lamivudine—Pharyngitis—Doxorubicin—bone cancer	0.000169	0.00151	CcSEcCtD
Lamivudine—Dysgeusia—Methotrexate—bone cancer	0.000167	0.00149	CcSEcCtD
Lamivudine—Connective tissue disorder—Doxorubicin—bone cancer	0.000167	0.00149	CcSEcCtD
Lamivudine—ABCC3—Fluoropyrimidine Activity—TP53—bone cancer	0.000167	0.0011	CbGpPWpGaD
Lamivudine—Immune system disorder—Epirubicin—bone cancer	0.000166	0.00148	CcSEcCtD
Lamivudine—Mediastinal disorder—Epirubicin—bone cancer	0.000166	0.00148	CcSEcCtD
Lamivudine—Back pain—Methotrexate—bone cancer	0.000165	0.00147	CcSEcCtD
Lamivudine—Chills—Epirubicin—bone cancer	0.000165	0.00147	CcSEcCtD
Lamivudine—ABCC3—NRF2 pathway—TGFBR2—bone cancer	0.000164	0.00109	CbGpPWpGaD
Lamivudine—ABCC3—NRF2 pathway—GSTP1—bone cancer	0.000164	0.00109	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—DHFR—bone cancer	0.000163	0.00108	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—DHFR—bone cancer	0.000163	0.00108	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—DHFR—bone cancer	0.000163	0.00108	CbGpPWpGaD
Lamivudine—Alopecia—Epirubicin—bone cancer	0.000162	0.00145	CcSEcCtD
Lamivudine—Vomiting—Cisplatin—bone cancer	0.000162	0.00144	CcSEcCtD
Lamivudine—Erythema multiforme—Doxorubicin—bone cancer	0.000161	0.00143	CcSEcCtD
Lamivudine—Rash—Cisplatin—bone cancer	0.00016	0.00143	CcSEcCtD
Lamivudine—Dermatitis—Cisplatin—bone cancer	0.00016	0.00143	CcSEcCtD
Lamivudine—Malnutrition—Epirubicin—bone cancer	0.00016	0.00143	CcSEcCtD
Lamivudine—Erythema—Epirubicin—bone cancer	0.00016	0.00143	CcSEcCtD
Lamivudine—Ill-defined disorder—Methotrexate—bone cancer	0.000159	0.00141	CcSEcCtD
Lamivudine—PGK1—Disease—DHFR—bone cancer	0.000158	0.00105	CbGpPWpGaD
Lamivudine—Anaemia—Methotrexate—bone cancer	0.000158	0.00141	CcSEcCtD
Lamivudine—Flatulence—Epirubicin—bone cancer	0.000158	0.00141	CcSEcCtD
Lamivudine—ABCC1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000157	0.00104	CbGpPWpGaD
Lamivudine—Tension—Epirubicin—bone cancer	0.000157	0.0014	CcSEcCtD
Lamivudine—Dysgeusia—Epirubicin—bone cancer	0.000157	0.0014	CcSEcCtD
Lamivudine—ABCC4—Fluoropyrimidine Activity—TP53—bone cancer	0.000157	0.00104	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000156	0.00104	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000156	0.00103	CbGpPWpGaD
Lamivudine—Nervousness—Epirubicin—bone cancer	0.000155	0.00139	CcSEcCtD
Lamivudine—Back pain—Epirubicin—bone cancer	0.000155	0.00138	CcSEcCtD
Lamivudine—ABCC4—NRF2 pathway—TGFBR2—bone cancer	0.000155	0.00102	CbGpPWpGaD
Lamivudine—ABCC4—NRF2 pathway—GSTP1—bone cancer	0.000155	0.00102	CbGpPWpGaD
Lamivudine—Malaise—Methotrexate—bone cancer	0.000154	0.00137	CcSEcCtD
Lamivudine—Muscle spasms—Epirubicin—bone cancer	0.000154	0.00137	CcSEcCtD
Lamivudine—Immune system disorder—Doxorubicin—bone cancer	0.000154	0.00137	CcSEcCtD
Lamivudine—Vertigo—Methotrexate—bone cancer	0.000154	0.00137	CcSEcCtD
Lamivudine—Mediastinal disorder—Doxorubicin—bone cancer	0.000153	0.00137	CcSEcCtD
Lamivudine—Leukopenia—Methotrexate—bone cancer	0.000153	0.00136	CcSEcCtD
Lamivudine—Chills—Doxorubicin—bone cancer	0.000153	0.00136	CcSEcCtD
Lamivudine—NT5C—Metabolism—GNA11—bone cancer	0.000152	0.00101	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—GNA11—bone cancer	0.000152	0.00101	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—GNA11—bone cancer	0.000152	0.00101	CbGpPWpGaD
Lamivudine—Nausea—Cisplatin—bone cancer	0.000151	0.00135	CcSEcCtD
Lamivudine—Alopecia—Doxorubicin—bone cancer	0.00015	0.00134	CcSEcCtD
Lamivudine—Cough—Methotrexate—bone cancer	0.000149	0.00133	CcSEcCtD
Lamivudine—Ill-defined disorder—Epirubicin—bone cancer	0.000148	0.00132	CcSEcCtD
Lamivudine—Convulsion—Methotrexate—bone cancer	0.000148	0.00132	CcSEcCtD
Lamivudine—Malnutrition—Doxorubicin—bone cancer	0.000148	0.00132	CcSEcCtD
Lamivudine—Erythema—Doxorubicin—bone cancer	0.000148	0.00132	CcSEcCtD
Lamivudine—Anaemia—Epirubicin—bone cancer	0.000148	0.00132	CcSEcCtD
Lamivudine—Flatulence—Doxorubicin—bone cancer	0.000146	0.0013	CcSEcCtD
Lamivudine—Chest pain—Methotrexate—bone cancer	0.000146	0.0013	CcSEcCtD
Lamivudine—Myalgia—Methotrexate—bone cancer	0.000146	0.0013	CcSEcCtD
Lamivudine—Arthralgia—Methotrexate—bone cancer	0.000146	0.0013	CcSEcCtD
Lamivudine—Tension—Doxorubicin—bone cancer	0.000145	0.0013	CcSEcCtD
Lamivudine—Dysgeusia—Doxorubicin—bone cancer	0.000145	0.00129	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000145	0.00129	CcSEcCtD
Lamivudine—Malaise—Epirubicin—bone cancer	0.000144	0.00129	CcSEcCtD
Lamivudine—DCK—Metabolism—NT5C3A—bone cancer	0.000144	0.000955	CbGpPWpGaD
Lamivudine—Discomfort—Methotrexate—bone cancer	0.000144	0.00128	CcSEcCtD
Lamivudine—Nervousness—Doxorubicin—bone cancer	0.000144	0.00128	CcSEcCtD
Lamivudine—Vertigo—Epirubicin—bone cancer	0.000144	0.00128	CcSEcCtD
Lamivudine—Syncope—Epirubicin—bone cancer	0.000144	0.00128	CcSEcCtD
Lamivudine—Leukopenia—Epirubicin—bone cancer	0.000143	0.00128	CcSEcCtD
Lamivudine—Back pain—Doxorubicin—bone cancer	0.000143	0.00128	CcSEcCtD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000143	0.000947	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—ENO2—bone cancer	0.000143	0.000947	CbGpPWpGaD
Lamivudine—Muscle spasms—Doxorubicin—bone cancer	0.000142	0.00127	CcSEcCtD
Lamivudine—Confusional state—Methotrexate—bone cancer	0.000141	0.00125	CcSEcCtD
Lamivudine—Loss of consciousness—Epirubicin—bone cancer	0.000141	0.00125	CcSEcCtD
Lamivudine—SLC22A3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000141	0.000931	CbGpPWpGaD
Lamivudine—Cough—Epirubicin—bone cancer	0.00014	0.00125	CcSEcCtD
Lamivudine—Anaphylactic shock—Methotrexate—bone cancer	0.00014	0.00124	CcSEcCtD
Lamivudine—Convulsion—Epirubicin—bone cancer	0.000139	0.00124	CcSEcCtD
Lamivudine—Infection—Methotrexate—bone cancer	0.000139	0.00124	CcSEcCtD
Lamivudine—PCYT2—Metabolism—CYP3A4—bone cancer	0.000138	0.000913	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—CYP3A4—bone cancer	0.000138	0.000913	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—CYP3A4—bone cancer	0.000138	0.000913	CbGpPWpGaD
Lamivudine—Ill-defined disorder—Doxorubicin—bone cancer	0.000137	0.00122	CcSEcCtD
Lamivudine—PCYT2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000137	0.000908	CbGpPWpGaD
Lamivudine—Nervous system disorder—Methotrexate—bone cancer	0.000137	0.00122	CcSEcCtD
Lamivudine—Anaemia—Doxorubicin—bone cancer	0.000137	0.00122	CcSEcCtD
Lamivudine—Thrombocytopenia—Methotrexate—bone cancer	0.000137	0.00122	CcSEcCtD
Lamivudine—Arthralgia—Epirubicin—bone cancer	0.000136	0.00121	CcSEcCtD
Lamivudine—Chest pain—Epirubicin—bone cancer	0.000136	0.00121	CcSEcCtD
Lamivudine—Myalgia—Epirubicin—bone cancer	0.000136	0.00121	CcSEcCtD
Lamivudine—Anxiety—Epirubicin—bone cancer	0.000136	0.00121	CcSEcCtD
Lamivudine—Skin disorder—Methotrexate—bone cancer	0.000136	0.00121	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000135	0.00121	CcSEcCtD
Lamivudine—Hyperhidrosis—Methotrexate—bone cancer	0.000135	0.0012	CcSEcCtD
Lamivudine—Discomfort—Epirubicin—bone cancer	0.000135	0.0012	CcSEcCtD
Lamivudine—Malaise—Doxorubicin—bone cancer	0.000134	0.00119	CcSEcCtD
Lamivudine—Dry mouth—Epirubicin—bone cancer	0.000133	0.00119	CcSEcCtD
Lamivudine—Vertigo—Doxorubicin—bone cancer	0.000133	0.00119	CcSEcCtD
Lamivudine—Anorexia—Methotrexate—bone cancer	0.000133	0.00119	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—ENO2—bone cancer	0.000133	0.00088	CbGpPWpGaD
Lamivudine—Syncope—Doxorubicin—bone cancer	0.000133	0.00118	CcSEcCtD
Lamivudine—PGK1—Metabolism—DHFR—bone cancer	0.000133	0.000878	CbGpPWpGaD
Lamivudine—Leukopenia—Doxorubicin—bone cancer	0.000133	0.00118	CcSEcCtD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000132	0.000875	CbGpPWpGaD
Lamivudine—Confusional state—Epirubicin—bone cancer	0.000132	0.00117	CcSEcCtD
Lamivudine—Oedema—Epirubicin—bone cancer	0.000131	0.00116	CcSEcCtD
Lamivudine—Anaphylactic shock—Epirubicin—bone cancer	0.000131	0.00116	CcSEcCtD
Lamivudine—Hypotension—Methotrexate—bone cancer	0.00013	0.00116	CcSEcCtD
Lamivudine—ABCC2—NRF2 pathway—GSTP1—bone cancer	0.00013	0.000863	CbGpPWpGaD
Lamivudine—ABCC2—NRF2 pathway—TGFBR2—bone cancer	0.00013	0.000863	CbGpPWpGaD
Lamivudine—Loss of consciousness—Doxorubicin—bone cancer	0.00013	0.00116	CcSEcCtD
Lamivudine—Infection—Epirubicin—bone cancer	0.00013	0.00116	CcSEcCtD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—IL3—bone cancer	0.00013	0.000859	CbGpPWpGaD
Lamivudine—ABCC3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000129	0.000856	CbGpPWpGaD
Lamivudine—Cough—Doxorubicin—bone cancer	0.000129	0.00115	CcSEcCtD
Lamivudine—Shock—Epirubicin—bone cancer	0.000129	0.00115	CcSEcCtD
Lamivudine—Convulsion—Doxorubicin—bone cancer	0.000128	0.00114	CcSEcCtD
Lamivudine—Nervous system disorder—Epirubicin—bone cancer	0.000128	0.00114	CcSEcCtD
Lamivudine—Thrombocytopenia—Epirubicin—bone cancer	0.000128	0.00114	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000127	0.00113	CcSEcCtD
Lamivudine—Skin disorder—Epirubicin—bone cancer	0.000127	0.00113	CcSEcCtD
Lamivudine—Hyperhidrosis—Epirubicin—bone cancer	0.000126	0.00113	CcSEcCtD
Lamivudine—Insomnia—Methotrexate—bone cancer	0.000126	0.00113	CcSEcCtD
Lamivudine—Arthralgia—Doxorubicin—bone cancer	0.000126	0.00112	CcSEcCtD
Lamivudine—Myalgia—Doxorubicin—bone cancer	0.000126	0.00112	CcSEcCtD
Lamivudine—Chest pain—Doxorubicin—bone cancer	0.000126	0.00112	CcSEcCtD
Lamivudine—Anxiety—Doxorubicin—bone cancer	0.000126	0.00112	CcSEcCtD
Lamivudine—Paraesthesia—Methotrexate—bone cancer	0.000125	0.00112	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000125	0.00112	CcSEcCtD
Lamivudine—Discomfort—Doxorubicin—bone cancer	0.000125	0.00111	CcSEcCtD
Lamivudine—Anorexia—Epirubicin—bone cancer	0.000125	0.00111	CcSEcCtD
Lamivudine—Dyspnoea—Methotrexate—bone cancer	0.000124	0.00111	CcSEcCtD
Lamivudine—Somnolence—Methotrexate—bone cancer	0.000124	0.00111	CcSEcCtD
Lamivudine—PGK1—Metabolism—GNA11—bone cancer	0.000124	0.000821	CbGpPWpGaD
Lamivudine—Dry mouth—Doxorubicin—bone cancer	0.000123	0.0011	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—DHFR—bone cancer	0.000123	0.000816	CbGpPWpGaD
Lamivudine—Dyspepsia—Methotrexate—bone cancer	0.000123	0.0011	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000122	0.00081	CbGpPWpGaD
Lamivudine—Hypotension—Epirubicin—bone cancer	0.000122	0.00109	CcSEcCtD
Lamivudine—Confusional state—Doxorubicin—bone cancer	0.000122	0.00109	CcSEcCtD
Lamivudine—NME2—Metabolism—ENO2—bone cancer	0.000122	0.000805	CbGpPWpGaD
Lamivudine—ABCC4—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000122	0.000805	CbGpPWpGaD
Lamivudine—SLC22A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000121	0.000804	CbGpPWpGaD
Lamivudine—Decreased appetite—Methotrexate—bone cancer	0.000121	0.00108	CcSEcCtD
Lamivudine—Oedema—Doxorubicin—bone cancer	0.000121	0.00108	CcSEcCtD
Lamivudine—Anaphylactic shock—Doxorubicin—bone cancer	0.000121	0.00108	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Methotrexate—bone cancer	0.00012	0.00107	CcSEcCtD
Lamivudine—Fatigue—Methotrexate—bone cancer	0.00012	0.00107	CcSEcCtD
Lamivudine—Infection—Doxorubicin—bone cancer	0.00012	0.00107	CcSEcCtD
Lamivudine—Pain—Methotrexate—bone cancer	0.000119	0.00106	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000119	0.00106	CcSEcCtD
Lamivudine—Shock—Doxorubicin—bone cancer	0.000119	0.00106	CcSEcCtD
Lamivudine—Nervous system disorder—Doxorubicin—bone cancer	0.000119	0.00106	CcSEcCtD
Lamivudine—Thrombocytopenia—Doxorubicin—bone cancer	0.000118	0.00105	CcSEcCtD
Lamivudine—Insomnia—Epirubicin—bone cancer	0.000118	0.00105	CcSEcCtD
Lamivudine—CMPK1—Metabolism—GSTP1—bone cancer	0.000118	0.000781	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—GSTP1—bone cancer	0.000118	0.000781	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—GSTP1—bone cancer	0.000118	0.000781	CbGpPWpGaD
Lamivudine—Skin disorder—Doxorubicin—bone cancer	0.000117	0.00105	CcSEcCtD
Lamivudine—Paraesthesia—Epirubicin—bone cancer	0.000117	0.00105	CcSEcCtD
Lamivudine—Hyperhidrosis—Doxorubicin—bone cancer	0.000117	0.00104	CcSEcCtD
Lamivudine—Dyspnoea—Epirubicin—bone cancer	0.000116	0.00104	CcSEcCtD
Lamivudine—Somnolence—Epirubicin—bone cancer	0.000116	0.00104	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—GNA11—bone cancer	0.000115	0.000763	CbGpPWpGaD
Lamivudine—Anorexia—Doxorubicin—bone cancer	0.000115	0.00103	CcSEcCtD
Lamivudine—Feeling abnormal—Methotrexate—bone cancer	0.000115	0.00103	CcSEcCtD
Lamivudine—Dyspepsia—Epirubicin—bone cancer	0.000115	0.00103	CcSEcCtD
Lamivudine—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.000115	0.00076	CbGpPWpGaD
Lamivudine—PGK1—Disease—TGFBR2—bone cancer	0.000115	0.00076	CbGpPWpGaD
Lamivudine—Gastrointestinal pain—Methotrexate—bone cancer	0.000114	0.00102	CcSEcCtD
Lamivudine—Decreased appetite—Epirubicin—bone cancer	0.000114	0.00101	CcSEcCtD
Lamivudine—Hypotension—Doxorubicin—bone cancer	0.000113	0.00101	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000113	0.00101	CcSEcCtD
Lamivudine—NME2—Metabolism—DHFR—bone cancer	0.000113	0.000747	CbGpPWpGaD
Lamivudine—Fatigue—Epirubicin—bone cancer	0.000113	0.001	CcSEcCtD
Lamivudine—PGK1—Metabolism—CYP3A4—bone cancer	0.000112	0.000744	CbGpPWpGaD
Lamivudine—Pain—Epirubicin—bone cancer	0.000112	0.000996	CcSEcCtD
Lamivudine—Constipation—Epirubicin—bone cancer	0.000112	0.000996	CcSEcCtD
Lamivudine—ABCC3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000112	0.000739	CbGpPWpGaD
Lamivudine—Urticaria—Methotrexate—bone cancer	0.000111	0.000988	CcSEcCtD
Lamivudine—Abdominal pain—Methotrexate—bone cancer	0.00011	0.000984	CcSEcCtD
Lamivudine—Body temperature increased—Methotrexate—bone cancer	0.00011	0.000984	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00011	0.000982	CcSEcCtD
Lamivudine—SLC22A3—Metabolism—NDUFA12—bone cancer	0.00011	0.000728	CbGpPWpGaD
Lamivudine—Insomnia—Doxorubicin—bone cancer	0.000109	0.000974	CcSEcCtD
Lamivudine—Paraesthesia—Doxorubicin—bone cancer	0.000109	0.000967	CcSEcCtD
Lamivudine—Dyspnoea—Doxorubicin—bone cancer	0.000108	0.000961	CcSEcCtD
Lamivudine—Feeling abnormal—Epirubicin—bone cancer	0.000108	0.00096	CcSEcCtD
Lamivudine—Somnolence—Doxorubicin—bone cancer	0.000107	0.000958	CcSEcCtD
Lamivudine—Gastrointestinal pain—Epirubicin—bone cancer	0.000107	0.000952	CcSEcCtD
Lamivudine—Dyspepsia—Doxorubicin—bone cancer	0.000106	0.000948	CcSEcCtD
Lamivudine—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000106	0.0007	CbGpPWpGaD
Lamivudine—NME2—Metabolism—GNA11—bone cancer	0.000105	0.000698	CbGpPWpGaD
Lamivudine—Decreased appetite—Doxorubicin—bone cancer	0.000105	0.000937	CcSEcCtD
Lamivudine—ABCC4—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000105	0.000694	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—CYP3A4—bone cancer	0.000104	0.000692	CbGpPWpGaD
Lamivudine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000104	0.00093	CcSEcCtD
Lamivudine—Fatigue—Doxorubicin—bone cancer	0.000104	0.000929	CcSEcCtD
Lamivudine—PCYT1A—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000104	0.000688	CbGpPWpGaD
Lamivudine—Urticaria—Epirubicin—bone cancer	0.000104	0.000925	CcSEcCtD
Lamivudine—Pain—Doxorubicin—bone cancer	0.000103	0.000921	CcSEcCtD
Lamivudine—Constipation—Doxorubicin—bone cancer	0.000103	0.000921	CcSEcCtD
Lamivudine—Abdominal pain—Epirubicin—bone cancer	0.000103	0.000921	CcSEcCtD
Lamivudine—Body temperature increased—Epirubicin—bone cancer	0.000103	0.000921	CcSEcCtD
Lamivudine—Hypersensitivity—Methotrexate—bone cancer	0.000103	0.000917	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000103	0.00068	CbGpPWpGaD
Lamivudine—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000102	0.000678	CbGpPWpGaD
Lamivudine—ABCC1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000101	0.00067	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—NDUFA12—bone cancer	0.000101	0.000669	CbGpPWpGaD
Lamivudine—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.000101	0.000668	CbGpPWpGaD
Lamivudine—Asthenia—Methotrexate—bone cancer	0.0001	0.000893	CcSEcCtD
Lamivudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.0001	0.000663	CbGpPWpGaD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	9.99e-05	0.000662	CbGpPWpGaD
Lamivudine—Feeling abnormal—Doxorubicin—bone cancer	9.96e-05	0.000888	CcSEcCtD
Lamivudine—Gastrointestinal pain—Doxorubicin—bone cancer	9.88e-05	0.000881	CcSEcCtD
Lamivudine—Pruritus—Methotrexate—bone cancer	9.87e-05	0.00088	CcSEcCtD
Lamivudine—Hypersensitivity—Epirubicin—bone cancer	9.62e-05	0.000858	CcSEcCtD
Lamivudine—PGK1—Metabolism—GSTP1—bone cancer	9.61e-05	0.000636	CbGpPWpGaD
Lamivudine—Urticaria—Doxorubicin—bone cancer	9.6e-05	0.000856	CcSEcCtD
Lamivudine—NME2—Metabolism—CYP3A4—bone cancer	9.55e-05	0.000633	CbGpPWpGaD
Lamivudine—Body temperature increased—Doxorubicin—bone cancer	9.55e-05	0.000852	CcSEcCtD
Lamivudine—Abdominal pain—Doxorubicin—bone cancer	9.55e-05	0.000852	CcSEcCtD
Lamivudine—Diarrhoea—Methotrexate—bone cancer	9.55e-05	0.000851	CcSEcCtD
Lamivudine—Asthenia—Epirubicin—bone cancer	9.37e-05	0.000835	CcSEcCtD
Lamivudine—Pruritus—Epirubicin—bone cancer	9.24e-05	0.000824	CcSEcCtD
Lamivudine—Dizziness—Methotrexate—bone cancer	9.23e-05	0.000823	CcSEcCtD
Lamivudine—NME1—Metabolism—ENO2—bone cancer	9.21e-05	0.00061	CbGpPWpGaD
Lamivudine—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.13e-05	0.000605	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—NT5C3A—bone cancer	9.11e-05	0.000603	CbGpPWpGaD
Lamivudine—Diarrhoea—Epirubicin—bone cancer	8.94e-05	0.000797	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—GSTP1—bone cancer	8.93e-05	0.000592	CbGpPWpGaD
Lamivudine—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.91e-05	0.00059	CbGpPWpGaD
Lamivudine—Hypersensitivity—Doxorubicin—bone cancer	8.9e-05	0.000794	CcSEcCtD
Lamivudine—Vomiting—Methotrexate—bone cancer	8.87e-05	0.000791	CcSEcCtD
Lamivudine—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.84e-05	0.000586	CbGpPWpGaD
Lamivudine—SLC22A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.82e-05	0.000584	CbGpPWpGaD
Lamivudine—Rash—Methotrexate—bone cancer	8.8e-05	0.000785	CcSEcCtD
Lamivudine—Dermatitis—Methotrexate—bone cancer	8.79e-05	0.000784	CcSEcCtD
Lamivudine—Headache—Methotrexate—bone cancer	8.74e-05	0.000779	CcSEcCtD
Lamivudine—ABCC1—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.74e-05	0.000579	CbGpPWpGaD
Lamivudine—Asthenia—Doxorubicin—bone cancer	8.67e-05	0.000773	CcSEcCtD
Lamivudine—Dizziness—Epirubicin—bone cancer	8.64e-05	0.00077	CcSEcCtD
Lamivudine—Pruritus—Doxorubicin—bone cancer	8.55e-05	0.000762	CcSEcCtD
Lamivudine—NME1—Metabolism—DHFR—bone cancer	8.55e-05	0.000566	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—NT5C3A—bone cancer	8.37e-05	0.000554	CbGpPWpGaD
Lamivudine—Vomiting—Epirubicin—bone cancer	8.3e-05	0.00074	CcSEcCtD
Lamivudine—Nausea—Methotrexate—bone cancer	8.29e-05	0.000739	CcSEcCtD
Lamivudine—Diarrhoea—Doxorubicin—bone cancer	8.27e-05	0.000737	CcSEcCtD
Lamivudine—Rash—Epirubicin—bone cancer	8.24e-05	0.000734	CcSEcCtD
Lamivudine—Dermatitis—Epirubicin—bone cancer	8.23e-05	0.000734	CcSEcCtD
Lamivudine—SLC22A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.22e-05	0.000544	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	8.2e-05	0.000543	CbGpPWpGaD
Lamivudine—Headache—Epirubicin—bone cancer	8.18e-05	0.000729	CcSEcCtD
Lamivudine—NME2—Metabolism—GSTP1—bone cancer	8.17e-05	0.000541	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—SPARC—bone cancer	8.06e-05	0.000534	CbGpPWpGaD
Lamivudine—Dizziness—Doxorubicin—bone cancer	7.99e-05	0.000712	CcSEcCtD
Lamivudine—NME1—Metabolism—GNA11—bone cancer	7.99e-05	0.000529	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—NDUFA12—bone cancer	7.92e-05	0.000524	CbGpPWpGaD
Lamivudine—PGK1—Disease—KIT—bone cancer	7.83e-05	0.000518	CbGpPWpGaD
Lamivudine—Nausea—Epirubicin—bone cancer	7.76e-05	0.000692	CcSEcCtD
Lamivudine—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.69e-05	0.000509	CbGpPWpGaD
Lamivudine—Vomiting—Doxorubicin—bone cancer	7.68e-05	0.000685	CcSEcCtD
Lamivudine—Rash—Doxorubicin—bone cancer	7.62e-05	0.000679	CcSEcCtD
Lamivudine—Dermatitis—Doxorubicin—bone cancer	7.61e-05	0.000679	CcSEcCtD
Lamivudine—SLC22A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.61e-05	0.000504	CbGpPWpGaD
Lamivudine—Headache—Doxorubicin—bone cancer	7.57e-05	0.000675	CcSEcCtD
Lamivudine—ABCC4—Hemostasis—GNA11—bone cancer	7.37e-05	0.000488	CbGpPWpGaD
Lamivudine—PGK1—Disease—BRAF—bone cancer	7.36e-05	0.000487	CbGpPWpGaD
Lamivudine—NME1—Metabolism—CYP3A4—bone cancer	7.24e-05	0.000479	CbGpPWpGaD
Lamivudine—Nausea—Doxorubicin—bone cancer	7.18e-05	0.00064	CcSEcCtD
Lamivudine—SLC22A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.09e-05	0.00047	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	6.97e-05	0.000461	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—NDUFA12—bone cancer	6.97e-05	0.000461	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—NDUFA12—bone cancer	6.89e-05	0.000456	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—IL3—bone cancer	6.68e-05	0.000443	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—NT5C3A—bone cancer	6.56e-05	0.000434	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—NDUFA12—bone cancer	6.43e-05	0.000425	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	6.35e-05	0.00042	CbGpPWpGaD
Lamivudine—DCK—Metabolism—ENO2—bone cancer	6.32e-05	0.000418	CbGpPWpGaD
Lamivudine—NME1—Metabolism—GSTP1—bone cancer	6.19e-05	0.00041	CbGpPWpGaD
Lamivudine—PGK1—Disease—MDM2—bone cancer	6.17e-05	0.000408	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—PTGS2—bone cancer	6.11e-05	0.000404	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—PTGS2—bone cancer	6.11e-05	0.000404	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—PTGS2—bone cancer	6.11e-05	0.000404	CbGpPWpGaD
Lamivudine—PGK1—Disease—PTGS2—bone cancer	5.94e-05	0.000394	CbGpPWpGaD
Lamivudine—DCK—Metabolism—DHFR—bone cancer	5.86e-05	0.000388	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.78e-05	0.000383	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—NT5C3A—bone cancer	5.77e-05	0.000382	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—NT5C3A—bone cancer	5.71e-05	0.000378	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.7e-05	0.000377	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—BRAF—bone cancer	5.59e-05	0.00037	CbGpPWpGaD
Lamivudine—DCK—Metabolism—GNA11—bone cancer	5.48e-05	0.000363	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	5.4e-05	0.000358	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—NT5C3A—bone cancer	5.32e-05	0.000353	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—BRAF—bone cancer	5.21e-05	0.000345	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—PTGS2—bone cancer	4.98e-05	0.00033	CbGpPWpGaD
Lamivudine—DCK—Metabolism—CYP3A4—bone cancer	4.97e-05	0.000329	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.83e-05	0.00032	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.82e-05	0.000319	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—MDM2—bone cancer	4.69e-05	0.00031	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—PTGS2—bone cancer	4.63e-05	0.000306	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—PLAU—bone cancer	4.38e-05	0.00029	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—MDM2—bone cancer	4.37e-05	0.000289	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—BRAF—bone cancer	4.28e-05	0.000284	CbGpPWpGaD
Lamivudine—DCK—Metabolism—GSTP1—bone cancer	4.25e-05	0.000281	CbGpPWpGaD
Lamivudine—NME2—Metabolism—PTGS2—bone cancer	4.23e-05	0.00028	CbGpPWpGaD
Lamivudine—PGK1—Disease—EGFR—bone cancer	4.21e-05	0.000279	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.16e-05	0.000275	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—BRAF—bone cancer	3.99e-05	0.000264	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—ENO2—bone cancer	3.99e-05	0.000264	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—NDUFA12—bone cancer	3.77e-05	0.000249	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—DHFR—bone cancer	3.7e-05	0.000245	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—ENO2—bone cancer	3.67e-05	0.000243	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—MDM2—bone cancer	3.59e-05	0.000238	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.58e-05	0.000237	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—GNA11—bone cancer	3.46e-05	0.000229	CbGpPWpGaD
Lamivudine—ABCC1—Disease—ENO2—bone cancer	3.43e-05	0.000227	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—DHFR—bone cancer	3.4e-05	0.000225	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—MDM2—bone cancer	3.35e-05	0.000222	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PTGS2—bone cancer	3.21e-05	0.000212	CbGpPWpGaD
Lamivudine—ABCC1—Disease—DHFR—bone cancer	3.18e-05	0.000211	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—GNA11—bone cancer	3.18e-05	0.000211	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—CYP3A4—bone cancer	3.14e-05	0.000208	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—NT5C3A—bone cancer	3.12e-05	0.000207	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—CYP3A4—bone cancer	2.88e-05	0.000191	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—ENO2—bone cancer	2.87e-05	0.00019	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.87e-05	0.00019	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—GSTP1—bone cancer	2.68e-05	0.000178	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—DHFR—bone cancer	2.67e-05	0.000177	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.66e-05	0.000176	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.56e-05	0.00017	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—ENO2—bone cancer	2.53e-05	0.000167	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—ENO2—bone cancer	2.5e-05	0.000166	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—GNA11—bone cancer	2.49e-05	0.000165	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—GSTP1—bone cancer	2.47e-05	0.000163	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—DHFR—bone cancer	2.35e-05	0.000155	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—ENO2—bone cancer	2.33e-05	0.000154	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—DHFR—bone cancer	2.32e-05	0.000154	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.31e-05	0.000153	CbGpPWpGaD
Lamivudine—ABCC1—Disease—TGFBR2—bone cancer	2.31e-05	0.000153	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—CYP3A4—bone cancer	2.26e-05	0.00015	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.25e-05	0.000149	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PTGS2—bone cancer	2.2e-05	0.000146	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—GNA11—bone cancer	2.19e-05	0.000145	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—GNA11—bone cancer	2.17e-05	0.000144	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—DHFR—bone cancer	2.16e-05	0.000143	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—GNA11—bone cancer	2.02e-05	0.000134	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—CYP3A4—bone cancer	1.99e-05	0.000132	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—CYP3A4—bone cancer	1.97e-05	0.00013	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—GSTP1—bone cancer	1.93e-05	0.000128	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—CYP3A4—bone cancer	1.83e-05	0.000121	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.81e-05	0.00012	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—TP53—bone cancer	1.76e-05	0.000117	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—GSTP1—bone cancer	1.7e-05	0.000113	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—GSTP1—bone cancer	1.68e-05	0.000111	CbGpPWpGaD
Lamivudine—ABCC1—Disease—KIT—bone cancer	1.57e-05	0.000104	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—GSTP1—bone cancer	1.57e-05	0.000104	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.52e-05	0.000101	CbGpPWpGaD
Lamivudine—ABCC1—Disease—BRAF—bone cancer	1.48e-05	9.8e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PTGS2—bone cancer	1.39e-05	9.2e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—ENO2—bone cancer	1.37e-05	9.05e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PTGS2—bone cancer	1.28e-05	8.46e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—DHFR—bone cancer	1.27e-05	8.4e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—MDM2—bone cancer	1.24e-05	8.21e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PTGS2—bone cancer	1.2e-05	7.91e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—GNA11—bone cancer	1.19e-05	7.85e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—CYP3A4—bone cancer	1.07e-05	7.12e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PTGS2—bone cancer	1e-05	6.63e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—GSTP1—bone cancer	9.19e-06	6.09e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PTGS2—bone cancer	8.81e-06	5.83e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PTGS2—bone cancer	8.72e-06	5.77e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—EGFR—bone cancer	8.47e-06	5.61e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PTGS2—bone cancer	8.12e-06	5.38e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PTGS2—bone cancer	4.76e-06	3.15e-05	CbGpPWpGaD
